Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Webcast Interview with CEO

19 Jul 2010 07:00

RNS Number : 5036P
ABCAM Plc
19 July 2010
 



For immediate release

19 July 2010

 

 

RNS REACH

 

ABCAM PLC

("Abcam" or "the Company")

 

Webcast interview with Jonathan Milner, CEO

 

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce that a webcast interview with Jonathan Milner, the Company's Chief Executive Officer, is ready to view at the London Stock Exchange website:

 

www.londonstockexchange.com/growing-company-interviews

 

In the interview, Dr Milner discusses the dynamics of the antibody marketplace and gives an insight into Abcam's history and operations, highlighting the importance of the internet to the Company's business model.

 

The interview marks the beginning of a series of webcasts hosted by the London Stock Exchange entitled Growing Company Interviews. The interviews are designed to give investors a better understanding of selected companies quoted on the London market.

 

 

For further information please contact:

 

Abcam + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

 

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

 

 

 

Notes for editors

 

About Abcam plc

 

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies, from over 250 suppliers. Abcam employs 270 staff in its four operating companies.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZQLFFBDFEBBV
Date   Source Headline
1st Oct 20204:41 pmRNSTotal Voting Rights
25th Sep 20201:33 pmRNSDirector/PDMR Shareholding
18th Sep 20202:19 pmRNSBlock listing Interim Review
18th Sep 20207:54 amRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSFull Year Results 2020
11th Sep 202010:34 amRNSNotice of Results
1st Sep 20207:52 amRNSTotal Voting Rights
4th Aug 202012:57 pmRNSTotal Voting Rights
23rd Jul 20207:00 amRNSChange of Adviser
23rd Jul 20207:00 amRNSFull Year Trading Update
2nd Jul 202010:11 amRNSTotal Voting Rights
16th Jun 202012:00 pmRNSDirectorate Change
1st Jun 20209:29 amRNSTotal Voting Rights
11th May 202011:00 amRNSStatement re Update on 2019 AGM Resolution Vote
1st May 202012:24 pmRNSTotal Voting Rights
22nd Apr 202010:11 amRNSHolding(s) in Company
21st Apr 20207:26 amRNSDirector/PDMR Shareholding
20th Apr 202010:19 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 Update
14th Apr 202010:07 amRNSHolding(s) in Company
9th Apr 20205:33 pmRNSIssue of Shares
2nd Apr 20209:50 amRNSTotal Voting Rights
27th Mar 20203:37 pmRNSHolding(s) in Company
9th Mar 20207:00 amRNSInterim results for 6 months ended 31 Dec 2019
4th Mar 20207:00 amRNSAcquisition of Marker Gene Technologies
2nd Mar 20203:43 pmRNSTotal Voting Rights
2nd Mar 20208:00 amRNSBlock listing Interim Review
4th Feb 202010:49 amRNSTotal Voting Rights
30th Jan 20207:00 amRNSAbcam expands cell engineering capabilities
28th Jan 20202:31 pmRNSHolding(s) in Company
28th Jan 20202:29 pmRNSDirector/PDMR Shareholding
14th Jan 20207:00 amRNSAppointment of Chief Financial Officer
10th Jan 20207:00 amRNSHalf Year Trading Update
2nd Jan 20209:45 amRNSTotal Voting Rights
2nd Jan 20207:00 amRNSTransaction complete between Abcam and Expedeon
19th Dec 201910:05 amRNSHolding(s) in Company
4th Dec 20193:37 pmRNSHolding(s) in Company
2nd Dec 20193:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20199:30 amRNSTotal Voting Rights
21st Nov 201911:42 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSAbcam Capital Markets Event
13th Nov 20194:45 pmRNSResult of AGM
11th Nov 20197:00 amRNSAbcam to acquire proteomics & immunology business
6th Nov 20199:06 amRNSDirector/PDMR Shareholding
1st Nov 201910:55 amRNSTotal Voting Rights
2nd Oct 20194:28 pmRNSHolding(s) in Company
2nd Oct 20191:49 pmRNSDirector/PDMR Shareholding
1st Oct 20192:22 pmRNSTotal Voting Rights
30th Sep 20191:35 pmRNSAnnual Financial Report
26th Sep 20192:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.